PPB - Services

Complaints, Feedback and Enquiry

๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ฒ ๐š๐ง๐ ๐๐จ๐ข๐ฌ๐จ๐ง๐ฌ ๐๐จ๐š๐ซ๐ ๐‡๐จ๐ฌ๐ญ๐ฌ ๐–๐จ๐ซ๐ค๐ฌ๐ก๐จ๐ฉ ๐ญ๐จ ๐’๐ญ๐ซ๐ž๐ง๐ ๐ญ๐ก๐ž๐ง ๐Œ๐ž๐๐ข๐œ๐š๐ฅ ๐ƒ๐ž๐ฏ๐ข๐œ๐ž ๐š๐ง๐ ๐ˆ๐ง-๐•๐ข๐ญ๐ซ๐จ ๐ƒ๐ข๐š๐ ๐ง๐จ๐ฌ๐ญ๐ข๐œ๐ฌ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐ข๐จ๐ง – August 23, 2023

Nairobi, Kenya –ย The Pharmacy and Poisons Board is currently hosting a three-day workshop aimed at enhancing the regulation of Medical Devices and In-Vitro Diagnostics. This initiative seeks to bolster the existing regulatory systems for these medical products.

The primary objective of the workshop is to tap into the collective expertise of national regulatory authorities in order to implement effective regulatory practices. This includes the adoption of quality management systems for medical devices, as well as the proper risk classification of both Medical Devices and In-Vitro Diagnostics.

During the event, Dr. F. M. Siyoi, the CEO of the PPB, underlined the significant regulatory achievements the organization has accomplished over the past decade. He also emphasized the commitment to further enhancing the regulatory framework and systems related to Medical Devices and Diagnostics.

The workshop has successfully gathered regulatory professionals from various parts of the world, including representatives from the United States Food and Drug Administration (US FDA), Health Sciences Authority of Singapore, ANVISA of Brazil, Therapeutic Goods Administration of Australia, and experts from the PPB itself. This global collaboration aims to collectively strengthen the oversight of these crucial medical products.


Public Relations

Leave a comment

Your email address will not be published. Required fields are marked *